These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 1957327)

  • 21. Eosinophilia-myalgia syndrome not associated with the ingestion of nutritional supplements.
    Clauw DJ; Flockhart DA; Mullins W; Katz P; Medsger TA
    J Rheumatol; 1994 Dec; 21(12):2385-7. PubMed ID: 7699648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. L-tryptophan contaminant 'peak E' induces the release of IL-5 and IL-10 by peripheral blood mononuclear cells from patients with functional somatic syndromes.
    Barth H; Klein R; Berg PA
    Clin Exp Immunol; 2001 Nov; 126(2):187-92. PubMed ID: 11703359
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Generation of quinoneimine intermediates in the bioactivation of 3-(N-phenylamino)alanine (PAA) by human liver microsomes: a potential link between eosinophilia-myalgia syndrome and toxic oil syndrome.
    Martínez-Cabot A; Messeguer A
    Chem Res Toxicol; 2007 Oct; 20(10):1556-62. PubMed ID: 17892268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Eosinophilia-myalgia syndrome not associated with L-tryptophan.
    Patmas MA
    N J Med; 1992 Apr; 89(4):285-6. PubMed ID: 1603435
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A heretofore undisclosed crux of eosinophilia-myalgia syndrome: compromised histamine degradation.
    Smith MJ; Garrett RH
    Inflamm Res; 2005 Nov; 54(11):435-50. PubMed ID: 16307217
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subchronic toxicity of 3-phenylamino alanine, an impurity in L-tryptophan reported to be associated with eosinophilia-myalgia syndrome.
    Sato F; Hagiwara Y; Kawase Y
    Arch Toxicol; 1995; 69(7):444-9. PubMed ID: 8526739
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Eosinophilia-myalgia syndrome: a recent syndrome serving as an alert to new diseases ahead.
    Sidransky H
    Mod Pathol; 1994 Sep; 7(7):806-10. PubMed ID: 7824518
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety concerns regarding impurities in L-Tryptophan associated with eosinophilia myalgia syndrome.
    Ko SM; Park JE; Heo IK; Shin YU; Kim YH; Son WC
    Food Chem Toxicol; 2023 Sep; 179():113946. PubMed ID: 37453474
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A contaminant of L-tryptophan enhances expression of dermal collagen in a murine model of eosinophilia myalgia syndrome.
    Suzuki S; Tourkina E; Ludwicka A; Hampton M; Bolster M; Maize J; Silver R
    Proc Assoc Am Physicians; 1996 Jul; 108(4):315-22. PubMed ID: 8863345
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Eosinophil-active cytokine from mononuclear cells cultured with L-tryptophan products: an unexpected consequence of endotoxin contamination.
    Kita H; Mayeno AN; Weyand CM; Goronzy JJ; Weiler DA; Lundy SK; Abrams JS; Gleich GJ
    J Allergy Clin Immunol; 1995 Jun; 95(6):1261-7. PubMed ID: 7797795
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chronic fatigue: a peculiar evolution of eosinophilia myalgia syndrome following treatment with L-tryptophan in four Italian adolescents.
    Priori R; Conti F; Luan FL; Arpino C; Valesini G
    Eur J Pediatr; 1994 May; 153(5):344-6. PubMed ID: 8033924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Eosinophilia-myalgia syndrome: coming to grips with a new illness.
    Kilbourne EM
    Epidemiol Rev; 1992; 14():16-36. PubMed ID: 1289111
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Continuing occurrence of eosinophilia myalgia syndrome in Canada.
    Spitzer WO; Haggerty JL; Berkson L; Davis W; Palmer W; Tamblyn R; Laprise R; Faith JM; Elmore JG; Horwitz RI
    Br J Rheumatol; 1995 Mar; 34(3):246-51. PubMed ID: 7728400
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Scleroderma, fasciitis, and eosinophilia associated with the ingestion of tryptophan.
    Silver RM; Heyes MP; Maize JC; Quearry B; Vionnet-Fuasset M; Sternberg EM
    N Engl J Med; 1990 Mar; 322(13):874-81. PubMed ID: 1690352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Eosinophilia-myalgia syndrome: the aftermath.
    Sack KE; Criswell LA
    South Med J; 1992 Sep; 85(9):878-82. PubMed ID: 1523446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Toxicology and safety study of L-tryptophan and its impurities for use in broiler feed.
    Ko SM; Park JE; Lee JY; Jeong DS; Kang J; Son KY; Heo IK; Shin YU; Kim YH; Son WC
    J Appl Toxicol; 2024 Feb; 44(2):184-200. PubMed ID: 37646433
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Eosinophilia-myalgia syndrome among the non-L-tryptophan users and pre-epidemic cases.
    Sullivan EA; Staehling N; Philen RM
    J Rheumatol; 1996 Oct; 23(10):1784-7. PubMed ID: 8895159
    [TBL] [Abstract][Full Text] [Related]  

  • 38. L-tryptophan-associated eosinophilic fasciitis prior to the 1989 eosinophilia-myalgia syndrome outbreak.
    Hibbs JR; Mittleman B; Hill P; Medsger TA
    Arthritis Rheum; 1992 Mar; 35(3):299-303. PubMed ID: 1536667
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tryptophan metabolism via the kynurenine pathway in patients with the eosinophilia-myalgia syndrome.
    Silver RM; McKinley K; Smith EA; Quearry B; Harati Y; Sternberg EM; Heyes MP
    Arthritis Rheum; 1992 Sep; 35(9):1097-105. PubMed ID: 1418026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Episodic eosinophilia-myalgia-like syndrome in a patient without L-tryptophan use: association with eosinophil activation and increased serum levels of granulocyte-macrophage colony-stimulating factor.
    Bochner BS; Friedman B; Krishnaswami G; Schleimer RP; Lichtenstein LM; Kroegel C
    J Allergy Clin Immunol; 1991 Oct; 88(4):629-36. PubMed ID: 1918729
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.